Limitations and confusing aspects of diagnostic testing for neurologic lyme disease in the United States

Elitza S. Theel, Maria E. Aguero-Rosenfeld, Bobbi Pritt, Patricia V. Adem, Gary P. Wormser

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

In the United States, laboratories frequently offer multiple different assays for testing of cerebrospinal fluid (CSF) samples to provide laboratory support for the diagnosis of central nervous system Lyme disease (CNSLD). Often included among these diagnostic tests are the same enzyme immunoassays and immunoblots that are routinely used to detect the presence of antibodies to Borrelia burgdorferi in serum. However, performing these assays on CSF alone may yield positive results simply from passive diffusion of serum antibodies into the CSF. In addition, such tests are only U.S. Food and Drug Administration cleared and well validated for testing serum, not CSF. When performed using CSF, positive results from these assays do not establish the presence of intrathecal antibody production to B. burgdorferi and therefore should not be offered. The preferred test to detect intrathecal production of antibodies to B. burgdorferi is the antibody index assay, which corrects for passive diffusion of serum antibodies into CSF and requires testing of paired serum and CSF collected at approximately the same time. However, this assay also has limitations and should only be used to establish a diagnosis of CNSLD in conjunction with patient exposure history, clinical presentation, and other laboratory findings.

Original languageEnglish (US)
Article numbere01406
JournalJournal of clinical microbiology
Volume57
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lyme Neuroborreliosis
Cerebrospinal Fluid
Borrelia burgdorferi
Serum
Antibodies
Antibody Formation
Clinical Laboratory Techniques
United States Food and Drug Administration
Immunoenzyme Techniques
Routine Diagnostic Tests
History

Keywords

  • Cerebrospinal fluid
  • Diagnostic tests
  • Lyme disease
  • Neurologic Lyme disease

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Limitations and confusing aspects of diagnostic testing for neurologic lyme disease in the United States. / Theel, Elitza S.; Aguero-Rosenfeld, Maria E.; Pritt, Bobbi; Adem, Patricia V.; Wormser, Gary P.

In: Journal of clinical microbiology, Vol. 57, No. 1, e01406, 01.01.2019.

Research output: Contribution to journalReview article

Theel, Elitza S. ; Aguero-Rosenfeld, Maria E. ; Pritt, Bobbi ; Adem, Patricia V. ; Wormser, Gary P. / Limitations and confusing aspects of diagnostic testing for neurologic lyme disease in the United States. In: Journal of clinical microbiology. 2019 ; Vol. 57, No. 1.
@article{5f94972496274983bbb69315b60110f0,
title = "Limitations and confusing aspects of diagnostic testing for neurologic lyme disease in the United States",
abstract = "In the United States, laboratories frequently offer multiple different assays for testing of cerebrospinal fluid (CSF) samples to provide laboratory support for the diagnosis of central nervous system Lyme disease (CNSLD). Often included among these diagnostic tests are the same enzyme immunoassays and immunoblots that are routinely used to detect the presence of antibodies to Borrelia burgdorferi in serum. However, performing these assays on CSF alone may yield positive results simply from passive diffusion of serum antibodies into the CSF. In addition, such tests are only U.S. Food and Drug Administration cleared and well validated for testing serum, not CSF. When performed using CSF, positive results from these assays do not establish the presence of intrathecal antibody production to B. burgdorferi and therefore should not be offered. The preferred test to detect intrathecal production of antibodies to B. burgdorferi is the antibody index assay, which corrects for passive diffusion of serum antibodies into CSF and requires testing of paired serum and CSF collected at approximately the same time. However, this assay also has limitations and should only be used to establish a diagnosis of CNSLD in conjunction with patient exposure history, clinical presentation, and other laboratory findings.",
keywords = "Cerebrospinal fluid, Diagnostic tests, Lyme disease, Neurologic Lyme disease",
author = "Theel, {Elitza S.} and Aguero-Rosenfeld, {Maria E.} and Bobbi Pritt and Adem, {Patricia V.} and Wormser, {Gary P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/JCM.01406-18",
language = "English (US)",
volume = "57",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Limitations and confusing aspects of diagnostic testing for neurologic lyme disease in the United States

AU - Theel, Elitza S.

AU - Aguero-Rosenfeld, Maria E.

AU - Pritt, Bobbi

AU - Adem, Patricia V.

AU - Wormser, Gary P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the United States, laboratories frequently offer multiple different assays for testing of cerebrospinal fluid (CSF) samples to provide laboratory support for the diagnosis of central nervous system Lyme disease (CNSLD). Often included among these diagnostic tests are the same enzyme immunoassays and immunoblots that are routinely used to detect the presence of antibodies to Borrelia burgdorferi in serum. However, performing these assays on CSF alone may yield positive results simply from passive diffusion of serum antibodies into the CSF. In addition, such tests are only U.S. Food and Drug Administration cleared and well validated for testing serum, not CSF. When performed using CSF, positive results from these assays do not establish the presence of intrathecal antibody production to B. burgdorferi and therefore should not be offered. The preferred test to detect intrathecal production of antibodies to B. burgdorferi is the antibody index assay, which corrects for passive diffusion of serum antibodies into CSF and requires testing of paired serum and CSF collected at approximately the same time. However, this assay also has limitations and should only be used to establish a diagnosis of CNSLD in conjunction with patient exposure history, clinical presentation, and other laboratory findings.

AB - In the United States, laboratories frequently offer multiple different assays for testing of cerebrospinal fluid (CSF) samples to provide laboratory support for the diagnosis of central nervous system Lyme disease (CNSLD). Often included among these diagnostic tests are the same enzyme immunoassays and immunoblots that are routinely used to detect the presence of antibodies to Borrelia burgdorferi in serum. However, performing these assays on CSF alone may yield positive results simply from passive diffusion of serum antibodies into the CSF. In addition, such tests are only U.S. Food and Drug Administration cleared and well validated for testing serum, not CSF. When performed using CSF, positive results from these assays do not establish the presence of intrathecal antibody production to B. burgdorferi and therefore should not be offered. The preferred test to detect intrathecal production of antibodies to B. burgdorferi is the antibody index assay, which corrects for passive diffusion of serum antibodies into CSF and requires testing of paired serum and CSF collected at approximately the same time. However, this assay also has limitations and should only be used to establish a diagnosis of CNSLD in conjunction with patient exposure history, clinical presentation, and other laboratory findings.

KW - Cerebrospinal fluid

KW - Diagnostic tests

KW - Lyme disease

KW - Neurologic Lyme disease

UR - http://www.scopus.com/inward/record.url?scp=85059410566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059410566&partnerID=8YFLogxK

U2 - 10.1128/JCM.01406-18

DO - 10.1128/JCM.01406-18

M3 - Review article

C2 - 30257905

AN - SCOPUS:85059410566

VL - 57

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

M1 - e01406

ER -